Abstract
OBJECTIVE: To assess how well steroidal nasal sprays and oral steroids work for treating CRS. METHODS: Two hundred patients with CRS were included in a randomized controlled experiment. The patients were split into two groups: Group B received steroidal nasal sprays (fluticasone propionate 110 mcg/day in each nostril for 12 weeks) and Group A received oral steroids (prednisolone 30 mg/day for 14 days, followed by tapering over 7 days). The "Sino-Nasal Outcome Test (SNOT-22)" was used to quantify improvement in symptoms, the "Rhinosinusitis Disability Index (RSDI)" was used to measure quality of life, and the recurrence rate was measured at the 6-month follow-up. RESULTS: At 12 weeks, SNOT-22 and RSDI scores significantly improved with both oral steroids and steroidal nasal sprays (P < 0.05). At the 6-month follow-up, however, oral steroids had a greater recurrence rate (25% vs. 12%, P = 0.02) when compared to steroidal nasal sprays. The two groups' adverse effects were similar and of low severity. CONCLUSION: In conclusion, nasal sprays containing steroids seem to be a safer and more successful option than oral steroids for treating CRS, making them worthy of being used as the first line of treatment.